NO954245L - Cyklosporinholdig pulverblanding - Google Patents

Cyklosporinholdig pulverblanding

Info

Publication number
NO954245L
NO954245L NO954245A NO954245A NO954245L NO 954245 L NO954245 L NO 954245L NO 954245 A NO954245 A NO 954245A NO 954245 A NO954245 A NO 954245A NO 954245 L NO954245 L NO 954245L
Authority
NO
Norway
Prior art keywords
cyclosporin
present
organic solvent
containing powder
powder mixture
Prior art date
Application number
NO954245A
Other languages
English (en)
Other versions
NO954245D0 (no
Inventor
Jung Woo Kim
Hee Jong Shin
Joon Kyu Park
Kyeong Bok Min
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Publication of NO954245D0 publication Critical patent/NO954245D0/no
Publication of NO954245L publication Critical patent/NO954245L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelse angår en cyklosporin- holdig pulverblanding som omfatter cyklosporin et ikke-ionisk hydrofilt overflateaktivt middel og en porøs bærer. I tillegg angår den foreliggende opp- finnelse en fremgangsmåte til å fremstille den cyklosporinholdige pulverblanding som omfatter å oppløse cyklosporin og et ikke-ionisk hydrofilt overflateaktivt middel i et organisk oppløsnings- middel, tilsette en porøs bærer til den resulterende oppløsning og deretter inndampe det organiske oppløsningsmiddel fra blandingen. Pulver- blandingen i henhold til foreliggende oppfinnelse er stabil og krever ikke spesiell fremstillingsteknikk når den formuleres. I tillegg siden pulverblandingen i henhold til foreliggende oppfinnelse ikke innehol- der et organisk oppløsningsmiddel er nødvendighe- ten av en spesiell innpakning ekskludert. Videre tilveiebringer blandingen i henhold til foreliggende oppfinnelse en forbedret biotilgjengelighet som resulterer i reduksjon av enkeltdose og derfor kan bidra til reduksjon av bivirkninger assosiert med cyklosporin.
NO954245A 1994-02-25 1995-10-24 Cyklosporinholdig pulverblanding NO954245L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19940003490 1994-02-25
PCT/KR1994/000125 WO1995022982A1 (en) 1994-02-25 1994-09-16 Cyclosporin-containing powder composition

Publications (2)

Publication Number Publication Date
NO954245D0 NO954245D0 (no) 1995-10-24
NO954245L true NO954245L (no) 1995-12-22

Family

ID=19377804

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954245A NO954245L (no) 1994-02-25 1995-10-24 Cyklosporinholdig pulverblanding

Country Status (10)

Country Link
US (1) US5543393A (no)
EP (1) EP0702562A1 (no)
JP (1) JPH09501701A (no)
KR (1) KR0146671B1 (no)
CN (1) CN1121694A (no)
AU (1) AU7709194A (no)
CA (1) CA2161343A1 (no)
FI (1) FI955042A (no)
NO (1) NO954245L (no)
WO (1) WO1995022982A1 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69426408T2 (de) 1993-09-28 2001-07-12 Novartis Ag, Basel Herstellung von Weichgelatinekapseln
RU2158601C2 (ru) 1994-11-03 2000-11-10 Новартис Аг Новые лекарственные формы циклоспорина для орального применения с простым составом и высокой биодоступностью и способ их получения
US6022536A (en) * 1995-08-09 2000-02-08 Schering Corporation Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
DE19549852B4 (de) * 1995-11-29 2009-06-04 Novartis Ag Cyclosporin enthaltende Präparate
KR980008239A (ko) * 1996-07-26 1998-04-30 김충환 사이클로스포린-함유 약학적 조성물
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
KR19990047897A (ko) * 1997-12-05 1999-07-05 김충환 사이클로스포린 함유 약학적 조성물
ATE404172T1 (de) 1998-12-30 2008-08-15 Dexcel Ltd Dispergierbares konzentrat zur verabreichung von cyclosporin
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
EP1227793A1 (en) * 1999-11-02 2002-08-07 Cipla Ltd. Cyclosporin formulation
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
MXPA02007052A (es) * 2000-01-20 2002-12-13 Basilea Pharmaceutica Ag Composiciones que se administran nasalmente y que contienen peptidos ciclicos.
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
US6956098B2 (en) * 2002-09-20 2005-10-18 E. I. Du Pont De Nemours And Company High modulus polyimide compositions useful as dielectric substrates for electronics applications, and methods relating thereto
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
FR2873923B1 (fr) * 2004-08-05 2007-01-12 Gattefosse Holding Sa Particule solide anhydre contenant une composition lipidique liquide et composition pharmaceutique contenant lesdites particules
JP5036029B2 (ja) * 2005-06-10 2012-09-26 旭化成ファーマ株式会社 安定化されたミルナシプラン製剤
US8309128B2 (en) 2005-06-10 2012-11-13 Pierre Fabre Medicament Stabilized milnacipran formulation
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
HU205861B (en) * 1986-12-19 1992-07-28 Sandoz Ag Process for producing hydrosole of pharmaceutically effective material
JP2536876B2 (ja) * 1987-07-31 1996-09-25 寛治 高田 シクロスポリンの溶解性粉末状製剤
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
BE1003009A5 (fr) * 1989-02-09 1991-10-22 Sandoz Sa Nouvelles compositions pharmaceutiques a base de cyclosporines.
US5135934A (en) * 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents

Also Published As

Publication number Publication date
FI955042A (fi) 1995-11-29
NO954245D0 (no) 1995-10-24
EP0702562A1 (en) 1996-03-27
CN1121694A (zh) 1996-05-01
FI955042A0 (fi) 1995-10-23
CA2161343A1 (en) 1995-08-31
AU7709194A (en) 1995-09-11
JPH09501701A (ja) 1997-02-18
KR950024770A (ko) 1995-09-15
KR0146671B1 (ko) 1998-08-17
US5543393A (en) 1996-08-06
WO1995022982A1 (en) 1995-08-31

Similar Documents

Publication Publication Date Title
NO954245L (no) Cyklosporinholdig pulverblanding
YU96602A (sh) Postupak za spravljanje smeše
NO975320L (no) Kontinuerlige, fluorkjemiske mikrodispersjoner for avlevering av farmasöytiske midler
TR200200008T2 (tr) Fenofibratı ihtiva eden farmasötik bileşim ve bu bileşimin hazırlanması için yöntem
FI964624A0 (fi) Menetelmä duokarmysiinijohdannaisten stabiloimiseksi
NO994266D0 (no) Hydrofile binære systemer for administrasjon av cyklosporin
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
ZA921804B (en) Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them.
BG106527A (en) Pharmaceutically active sulfonamide derivatives
DK0750618T3 (da) Oxazolidinonderivater og farmaceutiske præparater indeholdende dem
ES8505364A1 (es) Un procedimiento para la preparacion 1-imidazoles y 1h-1, 2, 4-triazoles
DE60024491D1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
DE69808463D1 (de) Selbstemulgierende formulierung enthaltend saure lipophile verbindungen
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
FI923385A0 (fi) Foerfarande foer framstaellning av en oral farmaceutisk sammansaettning som innehaoller cyklosporin.
RU96120199A (ru) Иммуносупрессорная композиция, содержащая циклоспорин, и способ ее получения
EP0264259B1 (en) Stabilized pharmaceutical compositions
IL148241A0 (en) A composition for inhalation containing delta-9-tetrahydrocannabinol
ES8506621A1 (es) Procedimiento de preparar nuevas bencensulfonil-lactamas
AU3777197A (en) Cyclosporin formulation
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
DK159016C (da) Fremgangsmaade til fremstilling af aromatiske isocyanater ved carbonylering af nitroforbindelser i naervaer af katalysatorer
WO1996007415B1 (en) Myocardial protection using benzothiazepinones
Stuchinskaya Decomposition of TCE/Air Mixture by Electron Beam Irradiation
IT1255696B (it) Composto con attivita' vasodilatatrice procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono